Chromatin Perturbation Promotes Susceptibility to Hypomethylating Agents

Abstract excerpt

Cancer-directed drugs are often clinically deployed without definitive understanding of their molecular mechanisms of action (MOA). Hypomethylating agents (HMAs), which result in the degradation of the DNA methyltransferase 1 (DNMT1), have been deployed for decades in the treatment of haematological malignancies 1,2 . The precise mechanism of action of these drugs, however, has been debated, rendering the design...

Topics

Open a Topic to create a Post that cites this publication.

• Acute Myeloid Leukemia Research
• Adenosine and Purinergic Signaling
• Autophagy in Disease and Therapy
• Cancer-related Molecular Pathways
• DNA Repair Mechanisms
• Histone Deacetylase Inhibitors Research
• Protein Degradation and Inhibitors
• Ubiquitin and proteasome pathways

Identifiers and source

Literature Corpus work

d11f6858-3c80-5cd5-bfde-12a00a0c0d00

DOI

10.1101/2025.07.28.666975